Baker Brothers Advisors - Q2 2024 holdings

$7.83 Billion is the total value of Baker Brothers Advisors's 95 reported holdings in Q2 2024. The portfolio turnover from Q1 2024 to Q2 2024 was 27.6% .

 Value Shares↓ Weighting
INCY SellIncyte Corporation$1,863,369,325
-9.6%
30,738,524
-15.0%
23.81%
-7.9%
BGNE  BeiGene, Ltd.sponsored adr$1,507,864,535
-8.8%
10,568,8970.0%19.27%
-7.1%
ACAD BuyACADIA Pharmaceuticals Inc.$696,766,135
-12.1%
42,877,916
+0.0%
8.90%
-10.4%
MDGL BuyMadrigal Pharmaceuticals, Inc.$553,201,134
+5.2%
1,974,590
+0.2%
7.07%
+7.1%
RVMD BuyRevolution Medicines, Inc.$293,756,383
+20.7%
7,569,090
+0.3%
3.75%
+23.0%
RYTM  Rhythm Pharmaceuticals, Inc.$262,716,867
-5.2%
6,398,3650.0%3.36%
-3.5%
INSM BuyInsmed Incorporated$239,594,546
+2474.7%
3,576,038
+942.6%
3.06%
+2517.1%
BCYC BuyBicycle Therapeutics plcsponsored ads$190,255,190
+54.6%
9,399,960
+90.2%
2.43%
+57.4%
SMMT NewSummit Therapeutics Inc.$181,133,33223,222,222
+100.0%
2.32%
KYMR  Kymera Therapeutics, Inc.$178,978,451
-25.7%
5,995,9280.0%2.29%
-24.4%
EWTX  Edgewise Therapeutics, Inc.$105,179,463
-1.3%
5,840,0590.0%1.34%
+0.6%
ALKS NewAlkermes plc$100,780,1994,181,751
+100.0%
1.29%
NewInsmed Incorporatednote 0.75% 6/1/2028$90,413,50042,850,000
+100.0%
1.16%
REPL BuyReplimune Group, Inc.$90,408,024
+15.9%
10,045,336
+5.2%
1.16%
+18.1%
DNLI  Denali Therapeutics Inc.$86,649,958
+13.2%
3,731,6950.0%1.11%
+15.2%
ABCL  AbCellera Biologics Inc.$81,475,894
-34.7%
27,525,6400.0%1.04%
-33.4%
NRIX  Nurix Therapeutics, Inc.$81,019,949
+42.0%
3,882,1250.0%1.04%
+44.6%
IMTX  Immatics N.V.$74,872,285
+10.6%
6,443,3980.0%0.96%
+12.6%
 Entrada Therapeutics, Inc.$69,337,921
+0.6%
4,865,8190.0%0.89%
+2.4%
RARE  Ultragenyx Pharmaceutical Inc.$60,275,082
-12.0%
1,466,5470.0%0.77%
-10.4%
STOK BuyStoke Therapeutics, Inc.$59,017,665
+29.8%
4,368,443
+29.7%
0.75%
+32.3%
NewInsmed Incorporatednote 1.75% 1/15/2025$56,192,30732,887,000
+100.0%
0.72%
NewKiniksa Pharmaceuticals International, plc$52,618,0902,818,323
+100.0%
0.67%
IMCR  Immunocore Holdings plcads$51,354,127
-47.9%
1,515,3180.0%0.66%
-46.9%
ARGX Sellargenx SEsponsored adr$48,123,196
-19.2%
111,904
-26.0%
0.62%
-17.7%
KOD  Kodiak Sciences Inc.$40,679,652
-55.3%
17,310,4900.0%0.52%
-54.5%
XENE  Xenon Pharmaceuticals Inc.$38,743,544
-9.4%
993,6790.0%0.50%
-7.8%
PRLD  Prelude Therapeutics Inc.$38,571,769
-19.6%
10,123,8240.0%0.49%
-18.1%
IDYA  IDEAYA Biosciences, Inc.$37,291,139
-20.0%
1,062,1230.0%0.48%
-18.5%
CERS  Cerus Corporation$34,280,117
-6.9%
19,477,3390.0%0.44%
-5.2%
 Sera Prognostics, Inc.$32,171,642
-34.9%
5,434,3990.0%0.41%
-33.7%
KRYS  Krystal Biotech, Inc.$31,206,680
+3.2%
169,9340.0%0.40%
+5.3%
CELC BuyCelcuity Inc.$30,712,140
-8.4%
1,874,978
+20.8%
0.39%
-6.9%
SellRoivant Sciences Ltd.$29,582,428
-62.1%
2,798,716
-62.3%
0.38%
-61.4%
IGMS BuyIGM Biosciences, Inc.$28,100,471
-28.8%
4,090,316
+0.0%
0.36%
-27.5%
CERE SellCerevel Therapeutics Holdings, Inc.$27,951,913
-58.7%
683,588
-57.3%
0.36%
-57.9%
AKRO SellAkero Therapeutics, Inc.$25,737,544
-62.4%
1,097,082
-59.6%
0.33%
-61.7%
DYN BuyDyne Therapeutics, Inc.$23,718,268
+193.1%
672,096
+135.8%
0.30%
+200.0%
NewAlumis Inc.$20,781,2501,562,500
+100.0%
0.27%
GLUE  Monte Rosa Therapeutics, Inc.$18,386,195
-47.0%
4,916,0950.0%0.24%
-46.0%
MRUS NewMerus N.V.$17,751,000300,000
+100.0%
0.23%
 Neurogene Inc.$16,594,386
-28.5%
456,0150.0%0.21%
-27.1%
 TScan Therapeutics, Inc.$16,291,033
-26.3%
2,784,7920.0%0.21%
-24.9%
SANA  Sana Biotechnology, Inc.$12,999,982
-45.4%
2,380,9490.0%0.17%
-44.5%
IMVT BuyImmunovant, Inc.$12,268,555
-10.7%
464,718
+9.3%
0.16%
-8.7%
XNCR  Xencor, Inc.$10,325,009
-14.5%
545,4310.0%0.13%
-12.6%
BuyNeumora Therapeutics, Inc.$10,170,118
+16.7%
1,034,600
+63.2%
0.13%
+19.3%
FATE BuyFate Therapeutics, Inc.$9,832,692
-26.3%
2,997,772
+64.9%
0.13%
-24.6%
 2seventy bio, Inc.$9,615,475
-28.0%
2,497,5260.0%0.12%
-26.8%
BMEA  Biomea Fusion, Inc.$9,490,271
-69.9%
2,108,9490.0%0.12%
-69.4%
CLDX  Celldex Therapeutics, Inc.$9,165,304
-11.8%
247,6440.0%0.12%
-10.0%
TSHA  Taysha Gene Therapies, Inc.$8,970,653
-22.0%
4,004,7560.0%0.12%
-20.1%
ATHA  Athira Pharma, Inc.$8,357,589
-3.3%
3,153,8070.0%0.11%
-0.9%
VERV  Verve Therapeutics, Inc.$8,254,666
-63.3%
1,691,5300.0%0.10%
-62.8%
RLAY  Relay Therapeutics, Inc.$7,563,963
-21.4%
1,160,1170.0%0.10%
-19.8%
MIRM  Mirum Pharmaceuticals, Inc.$6,512,374
+36.1%
190,4760.0%0.08%
+38.3%
 Tango Therapeutics, Inc.$6,435,000
+8.1%
750,0000.0%0.08%
+9.3%
BuyKALA BIO, Inc.$6,319,565
+197.4%
891,335
+234.3%
0.08%
+200.0%
NewDBV Technologies S.A.sponsored adr$5,853,0127,307,131
+100.0%
0.08%
DSGN BuyDesign Therapeutics, Inc.$5,679,235
-15.2%
1,695,294
+2.0%
0.07%
-13.1%
 Praxis Precision Medicines, Inc.$5,440,205
-32.2%
131,5330.0%0.07%
-30.7%
NewContineum Therapeutics, Inc.cl a$5,503,125312,500
+100.0%
0.07%
CRSP NewCRISPR Therapeutics AGnamen akt$5,401,000100,000
+100.0%
0.07%
 Prime Medicine, Inc.$5,286,315
-26.6%
1,028,4660.0%0.07%
-24.4%
CNTA NewCentessa Pharmaceuticals plcsponsored ads$4,959,384549,212
+100.0%
0.06%
NewHOOKIPA Pharma Inc.$4,810,2408,128,151
+100.0%
0.06%
 Sagimet Biosciences Inc.$4,726,091
-36.9%
1,381,8980.0%0.06%
-36.2%
CRNX NewCrinetics Pharmaceuticals, Inc.$4,654,890103,927
+100.0%
0.06%
 Talis Biomedical Corporation$4,402,992
-1.0%
508,3230.0%0.06%0.0%
OPT SellOpthea Limitedsponsored ads$4,195,090
-53.1%
2,173,622
-0.2%
0.05%
-51.8%
ALEC NewAlector, Inc.$4,209,779927,264
+100.0%
0.05%
NewSkye Bioscience, Inc.$4,005,000500,000
+100.0%
0.05%
PCVX  Vaxcyte, Inc.$3,691,306
+10.5%
48,8850.0%0.05%
+11.9%
ARCT NewArcturus Therapeutics Holdings Inc.$3,684,861151,329
+100.0%
0.05%
GBIO BuyGeneration Bio Co.$3,403,619
+125.3%
1,206,957
+225.1%
0.04%
+126.3%
 Enliven Therapeutics, Inc.$2,683,647
+32.9%
114,8330.0%0.03%
+36.0%
ADAP SellAdaptimmune Therapeutics plcsponsored adr$2,284,868
-86.6%
2,343,695
-78.3%
0.03%
-86.4%
 Leap Therapeutics, Inc.$2,297,463
-26.3%
1,172,1750.0%0.03%
-25.6%
MRSN  Mersana Therapeutics, Inc.$2,183,091
-55.1%
1,086,1150.0%0.03%
-54.1%
IPSC  Century Therapeutics, Inc.$2,033,523
-39.0%
797,4600.0%0.03%
-38.1%
 NewAmsterdam Pharma Company N.V.ordinary shares$1,860,047
-18.8%
96,8270.0%0.02%
-17.2%
SAGE SellSage Therapeutics, Inc.$1,857,342
-75.7%
171,026
-58.0%
0.02%
-75.0%
 vTv Therapeutics, Inc.cl a$1,718,565
-24.9%
97,3140.0%0.02%
-24.1%
CMPX  Compass Therapeutics, Inc.$1,557,630
-49.5%
1,557,6300.0%0.02%
-48.7%
TARA BuyProtara Therapeutics, Inc.$1,116,611
+39.5%
536,832
+168.9%
0.01%
+40.0%
PFE  Pfizer Inc.$979,300
+0.8%
35,0000.0%0.01%
+8.3%
AVTE SellAerovate Therapeutics, Inc.$1,044,039
-97.9%
628,939
-62.6%
0.01%
-97.9%
ACHL SellAchilles Therapeutics plcsponsored ads$903,645
-40.2%
1,108,767
-8.3%
0.01%
-36.8%
ALGS  Aligos Therapeutics, Inc.$726,740
-64.3%
2,076,4000.0%0.01%
-65.4%
PMVP  PMV Pharmaceuticals, Inc.$521,679
-4.7%
322,0240.0%0.01%0.0%
BCRX SellBioCryst Pharmaceuticals, Inc.$468,308
-99.1%
75,778
-99.3%
0.01%
-99.1%
 Acrivon Therapeutics, Inc.$306,733
-18.9%
52,8850.0%0.00%
-20.0%
FHTX  Foghorn Therapeutics Inc.$258,905
-14.3%
45,0270.0%0.00%
-25.0%
 Tyra Biosciences, Inc.$169,606
-2.5%
10,6070.0%0.00%0.0%
 Surrozen, Inc.w exp 8/11/2026$13,833
-45.0%
833,3330.0%0.00%
ISR ExitPerspective Therapeutics, Inc.$0-149,787
-100.0%
-0.00%
CABA ExitCabaletta Bio, Inc.$0-13,331
-100.0%
-0.00%
ExitMural Oncology plc$0-222,503
-100.0%
-0.01%
FDMT Exit4D Molecular Therapeutics, Inc.$0-100,000
-100.0%
-0.04%
ALPN ExitAlpine Immune Sciences, Inc.$0-81,578
-100.0%
-0.04%
HOOK ExitHOOKIPA Pharma Inc.$0-8,128,151
-100.0%
-0.07%
DBVT ExitDBV Technologies S.A.sponsored adr$0-14,614,264
-100.0%
-0.14%
KNSA ExitKiniksa Pharmaceuticals, Ltd.$0-2,809,577
-100.0%
-0.70%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2024-08-14
Signatures

The EDGAR filing(s) were signed by:

About Baker Brothers Advisors

Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.

Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.

The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.

Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Incyte Corporation45Q2 202437.6%
ACADIA Pharmaceuticals Inc.45Q2 202415.3%
BioCryst Pharmaceuticals, Inc.45Q2 20241.7%
Cerus Corporation45Q2 20240.9%
Insmed Incorporated45Q2 20243.1%
Biomarin Pharmaceuticals Inc.42Q3 20235.9%
Mirati Therapeutics, Inc.42Q4 20232.8%
Bluebird Bio Inc.41Q3 20230.3%
Heron Therapeutics, Inc.39Q3 20231.5%
DBV Technologies S.A.38Q1 20241.9%

View Baker Brothers Advisors's complete holdings history.

Latest significant ownerships (13-D/G)
Baker Brothers Advisors Q2 2024 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
KALA BIO, Inc.June 28, 2024891,33520.0%
Entrada Therapeutics, Inc.June 26, 20244,865,81913.2%
HOOKIPA Pharma Inc.June 14, 20249,813,15110.0%
INCYTE CORPJune 14, 202430,849,40116.1%
BICYCLE THERAPEUTICS plcMay 28, 20249,399,96019.9%
TScan Therapeutics, Inc.April 23, 20242,828,9386.1%
IGM Biosciences, Inc.March 28, 20244,145,70612.4%
MADRIGAL PHARMACEUTICALS, INC.March 25, 20242,070,54410.0%
vTv Therapeutics Inc.March 05, 2024122,6645.0%
2seventy bio, Inc.February 14, 20242,527,6725.0%

View Baker Brothers Advisors's complete significant-ownership history.

Latest filings
TypeFiled
42024-10-02
42024-10-02
N-PX2024-08-30
42024-08-22
SC 13D/A2024-08-22
13F-HR2024-08-14
42024-07-02
42024-07-02
42024-07-02
32024-06-28

View Baker Brothers Advisors's complete filings history.

Compare quarters

Export Baker Brothers Advisors's holdings